Comparing Gossamer Bio (NASDAQ:GOSS) and Moderna (NASDAQ:MRNA)

Moderna (NASDAQ:MRNA – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Institutional and Insider Ownership

75.3% of Moderna shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Moderna and Gossamer Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Moderna -110.46% -25.79% -15.85%
Gossamer Bio -159.49% N/A -112.10%

Valuation & Earnings

This table compares Moderna and Gossamer Bio”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Moderna $1.94 billion 40.14 -$2.82 billion ($7.10) -27.16
Gossamer Bio $78.42 million 0.88 -$170.37 million ($46.56) -0.24

Gossamer Bio has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Moderna has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Moderna and Gossamer Bio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna 4 15 6 0 2.08
Gossamer Bio 2 3 5 0 2.30

Moderna currently has a consensus price target of $120.25, indicating a potential downside of 37.64%. Gossamer Bio has a consensus price target of $246.40, indicating a potential upside of 2,090.22%. Given Gossamer Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Moderna.

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.